Trevena: Funding, Investors & Team (Oct 2026)
Trevena is a privately owned biopharmaceutical company based in King of Prussia, PA, focused on developing GPCR biased ligands. Founded in 2007, Trevena aims to turn innovative research on GPCR signaling into new medications. They are working on three programs: TRV027 for acute heart failure, TRV130 for postoperative pain, and TRV734 for acute and chronic pain. Additionally, Trevena has a number of drug discovery programs in progress. GPCRs are targeted by a significant percentage of current drugs, but there is room for improvement due to limited efficacy and side effects. Trevena's approach has potential to address these issues across various receptors and medical fields.
Trevena has raised $19.0M across 3 funding rounds on record, the most recent an undisclosed round of $2.0M announced in Jul 2024.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Trevena Company Profile and Key Stats
Latest funding round on record: Jul 2024.
Trevena Funding Rounds
Trevena raised $2.0M in a Post-IPO Equity announced in Jul 2022.
1.2 years later, an undisclosed round of $15.0M was announced in Sep 2023.
10 months later, an undisclosed round of $2.0M was announced in Jul 2024.
Trevena Founders and Leadership Team
No contact details are on record for this team yet.
Trevena Funding Compared to Other Biotechnology Startups
Trevena's latest round of $2.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Trevena in Biotechnology and King Of Prussia
Companies Similar to Trevena
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Trevena Funding FAQs
What does Trevena do?
Trevena is a privately owned biopharmaceutical company based in King of Prussia, PA, focused on developing GPCR biased ligands. Founded in 2007, Trevena aims to turn innovative research on GPCR signaling into new medications. They are working on three programs: TRV027 for acute heart failure, TRV130 for postoperative pain, and TRV734 for acute and chronic pain. Additionally, Trevena has a number of drug discovery programs in progress. GPCRs are targeted by a significant percentage of current drugs, but there is room for improvement due to limited efficacy and side effects. Trevena's approach has potential to address these issues across various receptors and medical fields.
How much funding has Trevena raised?
Trevena has raised $19.0M across 3 rounds on record. The most recent is an undisclosed round of $2.0M announced in Jul 2024.
When did Trevena last raise funding?
Trevena's most recent funding round on record is an undisclosed round of $2.0M, announced in Jul 2024.
Who founded Trevena?
FundedIQ lists Howard Rockman (Founder), Robert Lefkowitz (Founder) at Trevena.
Where is Trevena headquartered?
Trevena is based in King Of Prussia, Pennsylvania, United States.
How many employees does Trevena have?
Trevena is in the 11-50 employee band.
How does Trevena's funding compare to other Biotechnology startups?
Trevena's latest round of $2.0M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Trevena Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Trevena is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.